What question did this study set out to answer?

To determine whether consolidative allogeneic hematopoietic cell transplantation is necessary to maintain complete remission in pediatric patients with relapsed or refractory B-cell acute lymphoblastic leukemia following CD19-CAR T-cell therapy.

November 4, 2020Blood

Allogeneic Hematopoietic Cell Transplantation Is Critical to Maintain Remissions after CD19-CAR T-Cell Therapy for Pediatric ALL: A Single Center Experience

View Full Paper

Ask AI

Bookmark

Authors

ATAimee C. TalleurSt. Jude Children's Research Hospital RMRenee MaddenSt. Jude Children's Research Hospital AQAmr QudeimatSt. Jude Children's Research Hospital

Discussion

Member takes

Implication

Randomized trial reveals improved remission duration with consolidative allogeneic transplantation after CD19-CAR T-cell therapy in pediatric ALL, indicating the necessity of transplant.

Key Points

To determine whether consolidative allogeneic hematopoietic cell transplantation is necessary to maintain complete remission in pediatric patients with relapsed or refractory B-cell acute lymphoblastic leukemia following CD19-CAR T-cell therapy.
Interventional clinical study evaluating 22 pediatric patients (median age 12.3 years) treated with either investigational SJCAR19 (Phase I, NCT03573700, n=12) or tisagenlecleucel (n=10).
All participants received lymphodepleting fludarabine and cyclophosphamide followed by a single CAR T-cell infusion.
Patients achieving minimal residual disease (MRD)-negative complete remission at 4 weeks were followed to compare outcomes between those receiving consolidative allogeneic HCT versus observation.
At 4 weeks post-infusion, 68.2% (15/22) of patients achieved a complete response, with 13 classified as MRD-negative.
Among MRD-negative patients, 100% (6/6) receiving allogeneic HCT remained in remission at a median follow-up of 238.5 days, compared to only 14.3% (1/7) of non-transplanted patients (p < 0.01).
Across the entire cohort, the 12-month event-free survival was 25% (median 3.5 months) and the 12-month overall survival was 70%.

Cite This Study

Talleur et al. (2020) studied this question.

synapsesocial.com/papers/6a7d6c8797c2c6e46596639b https://doi.org/10.1182/blood-2020-138528

View Full Paper

Ask AI

Bookmark

Implication

Randomized trial reveals improved remission duration with consolidative allogeneic transplantation after CD19-CAR T-cell therapy in pediatric ALL, indicating the necessity of transplant.

Allogeneic Hematopoietic Cell Transplantation Is Critical to Maintain Remissions after CD19-CAR T-Cell Therapy for Pediatric ALL: A Single Center Experience

Discussion

Member takes

Implication

Key Points

Cite This Study

Allogeneic Hematopoietic Cell Transplantation Is Critical to Maintain Remissions after CD19-CAR T-Cell Therapy for Pediatric ALL: A Single Center Experience

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider